Revolution Medicines, Inc. (RVMD)

Market Cap	5.75B
Revenue (ttm)	11.58M
Net Income (ttm)	-436.37M
Shares Out	164.69M
EPS (ttm)	-3.86
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,211,816
Open	36.01
Previous Close	35.83
Day's Range	34.22 - 36.37
52-Week Range	15.44 - 38.73
Beta	1.54
Analysts	Strong Buy
Price Target	41.64 (+19.24%)
Earnings Date	May 6, 2024

About RVMD

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 13, 2020
• Employees: 378
• Stock Exchange: NASDAQ
• Ticker Symbol: RVMD

Financial Performance

In 2023, RVMD's revenue was $11.58 million, a decrease of -67.27% compared to the previous year's $35.38 million. Losses were -$436.37 million, 75.5% more than in 2022.

Analyst Forecast

According to 11 analysts, the average rating for RVMD stock is "Strong Buy." The 12-month stock price forecast is $41.64, which is an increase of 19.24% from the latest price.

Price Target

$41.64

(19.24% upside)

Analyst Consensus: Strong Buy